
Daré Bioscience, Inc. – NASDAQ:DARE
Daré Bioscience stock price today
Daré Bioscience stock price monthly change
Daré Bioscience stock price quarterly change
Daré Bioscience stock price yearly change
Daré Bioscience key metrics
Market Cap | 27.75M |
Enterprise value | 48.42M |
P/E | -2.64 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 7.43 |
PEG ratio | N/A |
EPS | -0.30 |
Revenue | N/A |
EBITDA | -28.49M |
Income | -28.87M |
Revenue Q/Q | N/A |
Revenue Y/Y | -99.97% |
Profit margin | -309.25% |
Oper. margin | -313.62% |
Gross margin | 0% |
EBIT margin | -313.62% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDaré Bioscience stock price history
Daré Bioscience stock forecast
Daré Bioscience financial statements
$12
Potential upside: 482.52%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 0 | -8.76M | |
---|---|---|---|
Sep 2023 | 1M | -8.29M | -829.91% |
Dec 2023 | 1.80M | -5.05M | -279.75% |
Mar 2024 | 9.30K | -6.75M | -72622.62% |
Payout ratio | 0% |
---|
2019 | 6180.9% |
---|---|
2020 | 17.02% |
2021 | |
2022 | |
2023 |
Jun 2023 | 23209954 | 25.92M | 111.72% |
---|---|---|---|
Sep 2023 | 25054030 | 27.34M | 109.14% |
Dec 2023 | 21282215 | 26.32M | 123.72% |
Mar 2024 | 13012722 | 24.01M | 184.53% |
Jun 2023 | -6.58M | 0 | 452.19K |
---|---|---|---|
Sep 2023 | -7.97M | -22.09K | 8.57M |
Dec 2023 | -8.17M | -607.33K | 5.30M |
Mar 2024 | -6.82M | -7.29K | 21.70K |
Daré Bioscience alternative data
Aug 2023 | 25 |
---|---|
Sep 2023 | 25 |
Oct 2023 | 25 |
Nov 2023 | 25 |
Dec 2023 | 25 |
Jan 2024 | 25 |
Feb 2024 | 25 |
Mar 2024 | 25 |
Apr 2024 | 25 |
May 2024 | 23 |
Jun 2024 | 23 |
Jul 2024 | 23 |
Daré Bioscience other data
Period | Buy | Sel |
---|---|---|
Jun 2018 | 140000 | 0 |
Apr 2019 | 454545 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | HAWLEY ROGER director | Common stock | 454,545 | $1.1 | $500,000 | ||
Purchase | HAWLEY ROGER director | Common stock | 140,000 | N/A | N/A | ||
Purchase | WALT DAVID R director | Common Stock | 591 | $2.09 | $1,234 | ||
Purchase | WALT DAVID R director | Common Stock | 1,700 | $2.08 | $3,529 | ||
Purchase | WALT DAVID R director | Common Stock | 4,500 | $2.09 | $9,401 | ||
Purchase | WALT DAVID R director | Common Stock | 4,460 | $2.12 | $9,442 | ||
Purchase | WALT DAVID R director | Common Stock | 4,500 | $2 | $9,014 | ||
Purchase | WALT DAVID R director | Common Stock | 4,311 | $2 | $8,631 | ||
Purchase | WALT DAVID R director | Common Stock | 4,350 | $2.03 | $8,835 | ||
Purchase | WALT DAVID R director | Common Stock | 4,500 | $2.08 | $9,338 |
Quarter | Transcript |
---|---|
Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Daré Bioscience stock today?
One share of Daré Bioscience stock can currently be purchased for approximately $2.06.
-
When is Daré Bioscience's next earnings date?
Unfortunately, Daré Bioscience's (DARE) next earnings date is currently unknown.
-
Does Daré Bioscience pay dividends?
No, Daré Bioscience does not pay dividends.
-
How much money does Daré Bioscience make?
Daré Bioscience has a market capitalization of 27.75M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 71.92% to 2.81M US dollars.
-
What is Daré Bioscience's stock symbol?
Daré Bioscience, Inc. is traded on the NASDAQ under the ticker symbol "DARE".
-
What is Daré Bioscience's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Daré Bioscience?
Shares of Daré Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Daré Bioscience's key executives?
Daré Bioscience's management team includes the following people:
- Ms. Sabrina Martucci Johnson Pres, Chief Executive Officer, Sec. & Director(age: 58, pay: $563,740)
- Mr. John A. Fair Chief Strategy Officer(age: 54, pay: $453,610)
- Ms. Lisa Walters-Hoffert Chief Financial Officer(age: 66, pay: $400,320)
-
How many employees does Daré Bioscience have?
As Jul 2024, Daré Bioscience employs 23 workers, which is 8% less then previous quarter.
-
When Daré Bioscience went public?
Daré Bioscience, Inc. is publicly traded company for more then 11 years since IPO on 10 Apr 2014.
-
What is Daré Bioscience's official website?
The official website for Daré Bioscience is darebioscience.com.
-
Where are Daré Bioscience's headquarters?
Daré Bioscience is headquartered at 3655 Nobel Drive, San Diego, CA.
-
How can i contact Daré Bioscience?
Daré Bioscience's mailing address is 3655 Nobel Drive, San Diego, CA and company can be reached via phone at 858 926 7655.
-
What is Daré Bioscience stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Daré Bioscience in the last 12 months, the avarage price target is $12. The average price target represents a 482.52% change from the last price of $2.06.
Daré Bioscience company profile:

Daré Bioscience, Inc.
darebioscience.comNASDAQ
23
Biotechnology
Healthcare
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
San Diego, CA 92122
CIK: 0001401914
ISIN: US23666P1012
CUSIP: 23666P101